Rebinyn May Interfere With Tests for COVID-19-related Coagulation Problems, Novo Nordisk Says
Novo Nordisk has issued a notice warning healthcare professionals that the hemophilia B treatment Rebinyn (nonacog…
Articles by Inês Martins, PhD
2 Proteins May Help Predict Acute Joint Bleeding in Severe Hemophilia A, Study Suggests
Blood levels of two proteins — C-reactive protein (CRP) and vascular endothelial growth factor (VEGF) — involved in…
Hemlibra Can Interfere with Tests of COVID-19-associated Coagulation Problems, Genentech Says
Genentech has issued a notice reminding healthcare professionals that its hemophilia A treatment Hemlibra (emicizumab) can…
Catalyst Preparing to Launch Phase 3 Trial of MarzAA in Hemophilia
After receiving guidance from both the U.S. Food and Drug Administration and the European Medicines Agency, Catalyst Biosciences…
New Recombinant Factor IX Products for Hemophilia B May ‘Revolutionize’ Treatment
Patient treatment for hemophilia B has come a long way since the introduction of factor IX (FIX) concentrates. In a recent…
Hemophilia A Patients with Transient Inhibitors to Factor VIII Can Usually Delay Therapy
Hemophilia A patients who receive replacement therapies of factor VIII often develop inhibitors against factor concentrates which hinders the effectiveness…
Hemophilia A Patients May See Promising Future Therapy in Embryonic Stem Cell Transplant
Transplants of embryonic stem (ES) cells that secrete the human factor VIII (FVIII) may be a promising therapeutic approach for…
New Long-Term Therapies for Hemophilia B Patients Reviewed
The genetic blood disorder hemophilia B, caused by factor IX (FIX) deficiency, can be effectively controlled with gene replacement therapies, particularly when…
Correct Diagnosis Required for Facial, Scalp Swelling in Children; Could Indicate Hemophilia
Facial and scalp swelling can be indicators of childhood hemophilia, but for children who are misdiagnosed and treated incorrectly, the effects…
Dimension Announces Positive Preclinical Results for an Adeno-Associated Virus Delivery of Factor VIII in Hemophilia A Treatment
Dimension Therapeutics recently revealed positive preclinical results from a novel adeno-associated virus (AAV) that delivers Factor VIII as a therapeutic approach for…